| Document |
Document Title |
|
JP3537769B2 |
Described are novel equilenin derivatives of general formula I methods for producing the same and medicaments containing these compounds. The new compounds have antioxidative activity and are usable for geroprophylaxis in women and men.
|
|
JP3535555B2 |
PURPOSE: To obtain compounds used for anti-inflammatory or the like with high efficiency by, after treating specific steroid derivatives with a methylating agent in the presence of a copper-based catalyst, hydrolyzing the formed 16α- me...
|
|
JP2004515454A |
The invention discloses formulations for administration through pressurized metered dose inhalers containing as active ingredient a glucocorticoid, in particular the (22R) epimer of budesonide, in solution in a hydrofluorocarbon propella...
|
|
JP2004143125A |
To obtain a novel steroid saponin compound contained in a plant of the genus Paris of the family of Liliaceae, and a stomach mucosa-protecting agent obtained by utilizing the compound.The novel steroid saponin compound is extracted from ...
|
|
JP2004512359A |
The invention relates to novel medicament compositions based on anticholinergics and corticosteroids, a method for the production thereof and the use thereof for treating respiratory conditions.
|
|
JP2004123757A |
To obtain a sulfatase inhibitor having no estrogenic active ingredient, because a compound restricting or preventing utilization of estrogenic substances is required for hormone dependent tumors.A new estratriene of formula (I) containin...
|
|
JP2004511435A |
A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a beta-adrenergic antagonist is described for treatment of circulatory di...
|
|
JP2004115408A |
To provide a cancericidal cell activity composition capable of being used as a new medicine which kills cancer cells and is effective for reducing / exterminating tumors and for suppressing the growth of the tumors.This cancericidal cell...
|
|
JP2004509971A |
The invention relates to 17alpha fluoroalkyl steroids of the general formula (I). STEROID (I), wherein R3 represents a group of the formula CnFmHo, wherein n=1, 2, 3, 4, 5 or 6, m>1 and m+o=2n+1. The invention further relates to methods ...
|
|
JP2004509132A |
The present invention is related to novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues, their use as antiglucocorticoids for the treatment and/or prophylaxis of disease associated to an excess of glucocorticoids. In particular,...
|
|
JP2004509131A |
A method of preparing 21-hydroxy-6,19-oxidoprogesterone, or an acylated or phosphorlated version thereof.
|
|
JP2004507495A |
Aldosterone receptor antagonists for the prevention and treatment of cognitive dysfunction are disclosed.
|
|
JP2004505093A |
The invention makes a 16α-substituted steroidal compound available having formula 1, wherein the dotted ring is a fully saturated, a fully aromatic or a saturated ring with a Δ5-10 double bond; R1 is (C1-C3)alkyl or (C2-C3)alkenyl, and...
|
|
JP3493037B2 |
PURPOSE: To efficiently obtain the new derivative for antitumor agents, antilithium agents, etc., by reacting specific hydroxypregnenes with acrylamides and then successively subjecting the reactional product to treatment with an organic...
|
|
JP2003531916A |
A compound of the formula: and pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein R groups are as defined by the present specification. The compounds may be formulated int...
|
|
JP2003300862A |
To obtain a compound which can effectively stimulate the function of sebum for the treatment of hyposeborrheic dry skin and is acceptable as a commercial product.Cosmetic of a sapogenin selected from diosgenin and hecogenin or a sapogeni...
|
|
JP2003277270A |
To provide a safe and effective carcinogensis preventing agent.The carcinogensis preventing agent contains preferably a cucurbitane-type triterpene glycoside obtained by treating Fructus Momordicae.
|
|
JP2003267873A |
To obtain a substance effective for bleaching of the suntan skin after ultraviolet irradiation and for preventing, ameliorating and treating pigmentation of the skin such as stains, freckles, liver spots, etc., and a composition containi...
|
|
JP2003525869A |
The invention discloses the use of 5-hydroxysapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.
|
|
JP2003524581A |
The invention discloses the use of a number of saponins and sapogenins, notably those of steroidal structure, in the treatment of cognitive disfunction and similar conditions. Methods of treatment, and pharmaceutical compositions are als...
|
|
JP2003523329A |
A method of increasing alertness in an individual by administering an effective amount of an alertness-increasing vomeropherin to the individual; and an alarm device that, when activated, emits an alertness-increasing vomeropherin. The m...
|
|
JP2003521519A |
The invention provides the use of rofleponide, its esters and salts in the manufacture of a medicament for use in the treatment of irritable bowel syndrome (IBS) and pharmaceutical formulations for use in such treatment.
|
|
JP2003520803A |
Certain steroid compounds which are 2. a. -cyano-4. a. , 5. a. -epoxy-3-oxo steroids notably trilostane, act on specific isoforms of the oestrogen receptor in human and animal cells. The compounds are used to treat certain conditions in ...
|
|
JP2003520238A |
The invention concerns the use of at least a compound selected in the group consisting of dehydroepiandrosterone, its chemical precursors, its chemical derivatives, its biological precursors and metabolic derivatives, for preparing a com...
|
|
JP2003519624A |
The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed
|
|
JP3418428B2 |
PURPOSE: To provide the novel steroid compounds whose steroid skeleton is bound at carbon atom 17 to a spiromethylene ring having progestational activity and antiprogenstational activities, and useful as contraceptive medicines. CONSTITU...
|
|
JP2003517472A |
The invention concerns a 3-methylene steroid derivative having general formula (1) wherein R1 is H or together with R3 forms a beta-epoxide or R1 is absent if there is a 5-10 or 4-5 double bond; R2 is (C1-C5) alkyl or CF3; R3 is betaH, b...
|
|
JP2003516414A |
A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when...
|
|
JP2003515611A5 |
|
|
JP2003513884A |
The present invention relates to the field of prodrugs of chemotherapeutic agents and method of use thereof.
|
|
JP2003513913A |
The present invention provides methods of treating, inhibiting or preventing pathogenic change resulting from vascular injury in a subject, particularly restenosis resulting substantially from angioplasty. The methods comprise administer...
|
|
JP2003512607A |
An allosteric site on muscarinic receptors is disclosed, together with its use for screening for compounds capable of modulating the binding of a primary ligand such as acetylcholine to the receptor. The site is characterised herein a se...
|
|
JP2003510333A |
The invention provides novel compounds of general formulae (I) and (II) as defined, their stereoisomers and racemic mixtures, their pharmaceutically acceptable pro-drugs and salts, which are useful in the treatment of cognitive dysfuncti...
|
|
JP2003510332A |
The invention discloses the use of sapogenin derivatives in the treatment of cognitive dysfunction and similar conditions. Methods of treatment and pharmaceutical compositions are also disclosed.
|
|
JP2003508541A |
Disclosed are novel, selective estrogens type having a steroid skeleton with a non-aromatic A-ring and a free or capped hydroxyl group at carbon atom No. 3. The estrogens satisfy general formula (I), in which R<1 >is H, (C1-C3)alkyl or (...
|
|
JP3377856B2 |
A compound represented by the following formula: X-Y-Z, wherein Y is represented by any of the formulae (III) to (V), X represents a monovalent group of a tetracycline compound, and Z represents a monovalent group of a stereoid compound ...
|
|
JP2003026591A |
To provide a specific anoretic agent, to provide a method for producing the anoretic agent by its synthesis, to provide an appetite suppressant composition containing the anoretic agent, and to provide an anorexiant.A compound represente...
|
|
JP2003502270A |
(57) [Summary] The three-dimensionally highly bent steroid 21-hydroxy-6,19-oxide progesterone (21OH-6OP) substantially lacks mineralocorticoid or glucocorticoid properties and affinity with MR or PR. It is a selective anti-glucocorticoid...
|
|
JP3366640B2 |
Novel compounds which are a glucocorticosteroid (GCS) chemically bound to a sugar, having the general formula GCS1-O-Sugar1 for colon- or ileum-specific delivery of the GCS to inflamed bowel mucosa, as well as processes for their prepara...
|
|
JP2002543069A |
An improved process for the preparation of single enantiomers of formula (I), and novel intermediates and processes thereto.
|
|
JP3357427B2 |
17-(3-Furyl) and (4-pyridazinyl)-5 beta ,14 beta -androstane derivatives of formula (I) wherein the symbol @ , the symbol ---, Y, R, R<1>, R<2> and R<3> have the meaning indicated in the specification. Processes of making the said compou...
|
|
JP3349554B2 |
The invention relates to a new process for preparing the compounds of formula (I): in which the rings A and B represent a 3-keto- DELTA <4>-6-R3, optionally in a form protected in position 3, or 3-keto- DELTA <1,4>-6-R3, R is methyl or -...
|
|
JP3346873B2 |
The invention relates to a process for preparing the compounds (I): where R is hydrogen or an ester residue, starting with the compound (II): by oxidative degradation, then fluorination in 6 and hydrofluorination of the epoxide. The comp...
|
|
JP2002322168A |
To provide pharmaceutical compounds which reduce undesirable effects occurred at the region where is apart from the target site.Pharmaceutical compounds represented by general formula (I) or their salts or solvates, which are effective i...
|
|
JP3333210B2 |
PCT No. PCT/EP94/01015 Sec. 371 Date Sep. 29, 1995 Sec. 102(e) Date Sep. 29, 1995 PCT Filed Mar. 31, 1994 PCT Pub. No. WO94/22899 PCT Pub. Date Oct. 13, 1994Epimers of the compound having the formula (I) are disclosed, both in their pure...
|
|
JP3328729B2 |
PCT No. PCT/FR92/00549 Sec. 371 Date May 25, 1994 Sec. 102(e) Date May 25, 1994 PCT Filed Jun. 18, 1992 PCT Pub. No. WO92/22300 PCT Pub. Date Dec. 23, 1992.The invention relates to the domain of medicinal chemistry. It concerns more part...
|
|
JP2002249489A |
To provide a method for industrially advantageously producing a compound having an epoxy group.The method for producing a compound having an epoxy group is characterized by reacting a compound having a carbon - carbon double bond with a ...
|
|
JP2002205997A |
To obtain a specific anorectic agent, to provide a method for producing the anorectic agent by synthesis, to obtain an anorectic composition containing the above agent, and to provide an anorectic method.The anorectic agent is a compound...
|
|
JP2002520287A |
This invention relates to the prophylaxis of choroidal neovascularisation in macular degeneration by the introduction of a suitable anti-inflammatory agent into the vitreous. In particular, it relates to the prophylaxis of neovascularisa...
|
|
JP2002518515A |
The present invention provides a new bioactive compound of formula (I), which has an antimicrobial activity against pathogenic microorganisms, and a process for production thereof. Also provided are a pharmaceutical composition comprisin...
|
